Clinical Trial Update: Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) [Phase 2]

View source ↗

Summary

TORAL is a Phase 2 trial evaluating toripalimab in combination with anlotinib for recurrent or metastatic nasopharyngeal carcinoma after platinum-based chemothe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED